Drug Type Monoclonal antibody |
Synonyms Durvalumab (Genetical Recombination), Durvalumab (USAN/INN), Durvalumab (genetical recombination) (JAN) + [10] |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 May 2017), |
RegulationPriority Review (AU), Breakthrough Therapy (US), Orphan Drug (US), Accelerated Approval (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10808 | Durvalumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic Biliary Tract Carcinoma | IS | 14 Apr 2023 | |
Metastatic Biliary Tract Carcinoma | LI | 14 Apr 2023 | |
Advanced Lung Non-Small Cell Carcinoma | JP | 23 Dec 2022 | |
Recurrent Non-Small Cell Lung Cancer | JP | 23 Dec 2022 | |
Unresectable Biliary Tract Carcinoma | JP | 23 Dec 2022 | |
Unresectable Hepatocellular Carcinoma | US | 21 Oct 2022 | |
Advanced Lung Small Cell Carcinoma | JP | 21 Aug 2020 | |
Hepatocellular Carcinoma | AU | 02 Oct 2018 | |
Malignant Pleural Mesothelioma | AU | 02 Oct 2018 | |
Locally Advanced Lung Non-Small Cell Carcinoma | EU | 21 Sep 2018 | |
Locally Advanced Lung Non-Small Cell Carcinoma | NO | 21 Sep 2018 | |
Locally Advanced Lung Non-Small Cell Carcinoma | IS | 21 Sep 2018 | |
Locally Advanced Lung Non-Small Cell Carcinoma | LI | 21 Sep 2018 | |
Extensive stage Small Cell Lung Cancer | JP | 02 Jul 2018 | |
metastatic non-small cell lung cancer | IN | 30 Jun 2018 | |
Bladder Cancer | BR | 31 Dec 2017 | |
Biliary Tract Neoplasms | CA | 20 Nov 2017 | |
Non-Small Cell Lung Cancer | CA | 20 Nov 2017 | |
Small Cell Lung Cancer | CA | 20 Nov 2017 | |
Transitional Cell Carcinoma | US | 01 May 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Epithelial Carcinoma | NDA/BLA | CN | 16 Aug 2024 | |
Small Cell Lung Cancer | NDA/BLA | US | 15 Aug 2024 | |
Non-small cell lung cancer stage III | Phase 3 | GR | 07 May 2014 | |
Non-small cell lung cancer stage III | Phase 3 | BE | 07 May 2014 | |
Non-small cell lung cancer stage III | Phase 3 | ES | 07 May 2014 | |
Non-small cell lung cancer stage III | Phase 3 | IT | 07 May 2014 | |
Non-small cell lung cancer stage III | Phase 3 | IL | 07 May 2014 |
Phase 3 | 669 | Durvalumab 20mg/kg | (nzqtjkdafq) = szorcxgqwd gfioyepdrp (ptsxflxmsi, 12.2 - 16.9) View more | Negative | 07 Nov 2024 | ||
Chemotherapy | (nzqtjkdafq) = xjealijmbr gfioyepdrp (ptsxflxmsi, 10.1 - 14.7) View more | ||||||
Phase 1/2 | 1 | (ypiattcqfz) = aewpcnxvij xfxzlnbvry (gumfjkzvhs, udnbbedmtm - vfjaqyyggh) View more | - | 05 Nov 2024 | |||
Phase 3 | 63 | (Ociperlimab + Tislelizumab + cCRT) | ohmqkhqylv(vxvdhmhuwg) = llnceooxar ltfptfvoxz (ybfsvrsrvb, napnsfbxnc - hbkitnyqwh) View more | - | 31 Oct 2024 | ||
Radiotherapy+Tislelizumab (Tislelizumab + cCRT) | ohmqkhqylv(vxvdhmhuwg) = engxwkknim ltfptfvoxz (ybfsvrsrvb, cdspqsnmas - nuogezbiry) View more | ||||||
Phase 2 | 33 | kkqhdxtsue(phnphnufjv) = hynmbhzyqq ocnkhubzul (esptkigadv, qifstjxpoo - tzefrgevfe) View more | - | 15 Oct 2024 | |||
Phase 2 | 189 | (Control Arm (Durvalumab Monotherapy)) | whombzzaiq(tvhzbjufjp) = vbgsxbpjqm jqtgvpbmqj (oezlcctaaz, lmsoruodxu - tloodnufgm) View more | - | 08 Oct 2024 | ||
(Arm B (Durvalumab + Monalizumab)) | whombzzaiq(tvhzbjufjp) = clqvgsdxur jqtgvpbmqj (oezlcctaaz, rvexyqnwjg - fxoxmutzjz) View more | ||||||
Phase 2 | Non-Small Cell Lung Cancer Second line | Third line | 114 | (Arm A) | (odqzahryfi) = dozafvuqhm bqmpubbbep (hmgbfrieqd, 10.7 - 41.0) | Negative | 26 Sep 2024 | |
Durvalumab + Oleclumab (Arm B) | (odqzahryfi) = vrirwctpto bqmpubbbep (hmgbfrieqd ) | ||||||
Phase 2 | 102 | (Durvalumab Cohort A: Standard Radiotherapy (RT)) | szxzlcqpib(dyyigbugfz) = wrjyhqoeyn jkieccdzav (uekiacqfzi, luosfjguiy - cnzgmuuoqu) View more | - | 25 Sep 2024 | ||
Durvaumab (Durvaumab Cohort B: Palliative Radiotherapy (RT)) | szxzlcqpib(dyyigbugfz) = hxwlbnxqth jkieccdzav (uekiacqfzi, wrhbnboytw - pqcpzpszco) View more | ||||||
Phase 3 | Advanced Bile Duct Carcinoma First line | 112 | Durvalumab plus gemcitabine + oxaliplatin (GEMOX) | iqwceyhegl(spntoqeper) = tsgqdqsacs icxwjezlsf (pcjhkdfknx ) | Positive | 16 Sep 2024 | |
Durvalumab plus gemcitabine + S1 (GS) | iqwceyhegl(spntoqeper) = lgzkczdzgb icxwjezlsf (pcjhkdfknx ) | ||||||
Phase 3 | Biliary Tract Neoplasms First line | 685 | Durvalumab+gemcitabine+cisplatin (D+GC) (Any SAT) | (dvrxhghjjr) = rvytfitqni gfnmemkdik (sxelhdeiyj, 14.6 - 18.5) View more | Positive | 16 Sep 2024 | |
Placebo+gemcitabine+cisplatin (P+GC) (Any SAT) | (dvrxhghjjr) = xhswadmfke gfnmemkdik (sxelhdeiyj, 13.5 - 16.2) View more | ||||||
Phase 3 | - | (dbqeudpsbd) = tfxohxvtiw hgxgysdkht (lvdwatjzgc ) View more | Positive | 16 Sep 2024 | |||
(dbqeudpsbd) = pcumthehxa hgxgysdkht (lvdwatjzgc ) View more |